UnderJungle

Hemp and Cannabis Community

Fagron Australia

Fagron's mission is to optimise and innovate personalised pharmaceutical care. Fagron is a multinational and publicly listed pharmaceutical company, founded in the Netherlands (Rotterdam) in 1990. Through a continuous focus on innovation, quality and solution-oriented thinking, Fagron obtained market leadership in pharmaceutical compounding. Fagron Australia is an affiliate of the multinational, located in Sydney. The company supplies pharmaceutical raw materials, equipment and innovative bases and suspending vehicles to compounding pharmacies all over Australia, New Zealand and South East Asia. Fagron Compounding Supplies Australia is fully compliant with TGA Good Wholesaling Practices and is licensed by the TGA to import restricted and controlled substances. Follow us on Twitter: @FagronAU Like us on Facebook: FagronAU Follow us on Instagram: @fagronau

Amplia Therapeutics Limited

Despite the recent success of immuno-oncology drugs, their use in fibrotic cancers (pancreatic, ovarian cancer) has been met with limited success. Recent research shows that Focal Adhesion Kinase (FAK) is significantly upregulated in these highly fibrotic tumours and therefore drugs targeting FAK have the potential to sensitize the tumour micro-environment to both I-O and chemotherapies. Inhibiting FAK can also directly boost the number of immune cells responsible for attacking tumours, further “amplifying” the effect of immuno-oncology treatment. Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a “pure play” inhibitor with superior specificity. The second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3.

ARTHROPHARM PTY LTD

Finley Pharmacy